Prelude Capital Management’s Assembly Biosciences ASMB Stock Holding History

Prelude Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-33	Closed	-$7K	–	1286
2020 Q3	$7K	Buy	+33	New	+$8.31K	﹤0.01%	1502
2019 Q3	–	Sell	-75	Closed	-$12K	–	1697
2019 Q2	$12K	Buy	+75	New	+$14.3K	﹤0.01%	1361
2018 Q3	–	Sell	-83	Closed	-$39K	–	1717
2018 Q2	$39K	Sell	83 -117	-59%	-$61.9K	﹤0.01%	1182
2018 Q1	$118K	Buy	+200	New	+$124K	0.01%	826
2017 Q4	–	Sell	-83	Closed	-$35K	–	1351
2017 Q3	$35K	Sell	83 -109	-57%	-$33.4K	﹤0.01%	1193
2017 Q2	$47K	Buy	+192	New	+$54.1K	﹤0.01%	1022
2016 Q4	–	Sell	-500	Closed	-$74.4K	–	1533
2016 Q3	$43K	Buy	500 +425	+567%	+$32.8K	﹤0.01%	1088
2016 Q2	$5K	Buy	+75	New	+$4.92K	﹤0.01%	1456
2015 Q2	–	Sell	-217	Closed	-$34K	–	1682
2015 Q1	$34K	Buy	+217	New	+$29.4K	﹤0.01%	1615

Other funds holding ASMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Prelude Capital Management's ASMB Position: Q4 2020 in Review

Prelude Capital Management sold out of Assembly Biosciences (ASMB) in Q4 2020, closing a stake of 33 shares — an estimated $7K sold.

Prelude Capital Management first reported a position in ASMB in Q1 2015 and held it in 9 quarters. The position peaked at $118K in Q1 2018. 109 funds tracked by Wall St. Rank hold ASMB as of Q4 2020.

Prelude Capital Management reported no remaining Assembly Biosciences position as of Q4 2020 after selling out during the quarter.
Prelude Capital Management sold 33 Assembly Biosciences shares in Q4 2020, an estimated $7K.
Prelude Capital Management first reported a position in Assembly Biosciences in Q1 2015 and held it in 9 quarters.
Prelude Capital Management's Assembly Biosciences position peaked at $118K in Q1 2018.
109 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.